Opioid Use Disorder Treatment Linkage at Strategic Touchpoints Using Buprenorphine (OUTLAST-B): Rationale, Design, and Evolution of a Randomized Controlled Trial-Journal of Psychiatry and Brain Science-CSCIED科技核心评价数据库-手机版

Opioid Use Disorder Treatment Linkage at Strategic Touchpoints Using Buprenorphine (OUTLAST-B): Rationale, Design, and Evolution of a Randomized Controlled Trial

Opioid Use Disorder Treatment Linkage at Strategic Touchpoints Using Buprenorphine (OUTLAST-B): Rationale, Design, and Evolution of a Randomized Controlled Trial

ES评分 0 浏览量：450 下载量：0

全文阅读下载引用收藏

DOI	10.20900/jpbs.20230010
刊名	Journal of Psychiatry and Brain Science JPBS
年，卷(期)	2023, 8(6)
作者	Courtney D. Nordeck*,Anjalee Sharma,Mishka Terplan,Kristi Dusek,Elizabeth Gilliams,Jan Gryczynski,
作者单位	1 Friends Research Institute, Baltimore, MD 21201, USA; 2 Behavioral Pharmacology Research Unit, Johns Hopkins School of Medicine, Baltimore, MD 21224, USA; 3 Baltimore City Health Department, Baltimore, MD 21202, USA
Abstract	Background: Despite the effectiveness and growing availability of treatment for opioid use disorder (OUD) with buprenorphine, many people with OUD do not access treatment services. This article describes the rationale, methodological design, evolution, and progress of an ongoing clinical trial of treatment linkage strategies for people with untreated OUD. Methods: The study, titled Opioid Use Disorder Treatment Linkage at Strategic Touchpoints using Buprenorphine (OUTLAST-B), uses “strategic touchpoints”, initially sexual health clinics and subsequently broadened to other service venues and participant social networks, for recruitment and screening. Adults with untreated OUD (target N = 360) are randomized to one of the three arms: Usual Care (UC, enhanced with overdose education and naloxone distribution), Patient Navigation (PN), or Patient Navigation with an immediate short-term bridge prescription for buprenorphine (PN + BUP). In the PN and PN + BUP arms, the Patient Navigator works with participants for 2 months to facilitate treatment entry and early retention, resolve barriers (e.g., ID cards, transportation), and provide motivational support. Results: The primary outcome is OUD treatment entry within 30 days of enrollment. Participants are assessed at baseline and followed at 3- and 6-months post-enrollment on measures of healthcare utilization, substance use, and general functioning. Challenges and recruitment adaptations pursuant to the COVID-19 pandemic are discussed. Conclusions: This study could provide insights on how to reach people with untreated OUD and link them to care through non-traditional routes. Trial Registration: The study is registered at ClinicalTrials.gov (NCT04991974).
KeyWord	opioid use disorder; buprenorphine; patient navigation
基金项目
页码	-

参考文献
相关文献

1. Keyes KM, Rutherford C, Hamilton A, Barocas JA, Gelberg KH, Mueller PP, et al. What is the prevalence of and trend in opioid use disorder in the United States from 2010 to 2019? Using multiplier approaches to estimate prevalence for an unknown population size. Drug Alcohol Depend Rep. 2022 Jun 1;3:100052. 2. National Institute on Drug Abuse. National Institute on Drug Abuse. Drug Overdose Death Rates. Available from: https://nida.nih.gov/research-topics/trends-statistics/overdose-death-rates. Accessed 2023 Dec 25. 3. Ma J, Bao YP, Wang RJ, Su MF, Liu MX, Li JQ, et al. Effects of medication-assisted treatment on mortality among opioids users: a systematic review and meta-analysis. Mol Psychiatry. 2019;24(12):1868-83. 4. National Academies of Sciences, Engineering, and Medicine. In Leshner AI, Mancher M, editors. Medications for Opioid Use Disorder Save Lives. Washington, (DC, US): The National Academies Press; 2019. p. 174. 5. Sordo L, Barrio G, Bravo MJ, Indave BI, Degenhardt L, Wiessing L, et al. Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies. BMJ. 2017 Apr 26;357:j1550. 6. Sullivan RW, Szczesniak LM, Wojcik SM. Bridge clinic buprenorphine program decreases emergency department visits. J Subst Abuse Treat. 2021;130:108410. 7. Wakeman SE, Rigotti NA, Chang Y, Herman GE, Erwin A, Regan S, et al. Effect of integrating substance use disorder treatment into primary care on inpatient and emergency department utilization. J Gen Intern Med. 2019;34:871-7. 8. Evans EA, Wilson D, Friedmann PD. Recidivism and mortality after in-jail buprenorphine treatment for opioid use disorder. Drug Alcohol Depend. 2022;231:109254. 9. Mattick RP, Breen C, Kimber J, Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev. 2014 Feb 6;2014(2):CD002207. 10. Substance Abuse and Mental Health Services Administration. Key substance use and mental health indicators in the United States: Results from the 2021 National Survey on Drug Use and Health. Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration. Available from: https://www.samhsa.gov/data/report/2021-nsduh-annual-national-report. Accessed 2023 Dec 20. 11. Gryczynski J, Nordeck CD, Mitchell SG, Page KR, Johnsen L, O’Grady KE, et al. Pilot studies examining feasibility of substance use disorder (SUD) screening and treatment linkage at urban sexually transmitted disease (STD) clinics. J Addict Med. 2017;11(5):350. 12. Percac-Lima S, Grant RW, Green AR, Ashburner JM, Gamba G, Oo S, et al. A Culturally Tailored Navigator Program for Colorectal Cancer Screening in a Community Health Center: A Randomized, Controlled Trial. J Gen Intern Med. 2009;24(2):211-7. 13. Bradford JB, Coleman S, Cunningham W. HIV System Navigation: An Emerging Model to Improve HIV Care Access. AIDS Patient Care STDs. 2007 Jun;21(s1):S-49. 14. Gardner LI, Metsch LR, Anderson-Mahoney P, Loughlin AM, del Rio C, Strathdee S, et al. Efficacy of a brief case management intervention to link recently diagnosed HIV-infected persons to care. AIDS. 2005 Mar 4;19(4):423-31. 15. Gryczynski J, Nordeck CD, Welsh C, Mitchell SG, O’Grady KE, Schwartz RP. Preventing Hospital Readmission for Patients With Comorbid Substance Use Disorder: A Randomized Trial. Ann Intern Med. 2021 Jul;174(7):899-909. 16. Carroll KM, Libby B, Sheehan J, Hyland N. Motivational interviewing to enhance treatment initiation in substance abusers: An effectiveness study. In: Psychosocial Treatments. New York (NY, US): Routledge; 2004. p. 35-40. 17. Coviello DM, Zanis DA, Wesnoski SA, Alterman AI. The effectiveness of outreach case management in re-enrolling discharged methadone patients. Drug Alcohol Depend. 2006;85(1):56-65. 18. Krupski A, Sears JM, Joesch JM, Estee S, He L, Dunn C, et al. Impact of brief interventions and brief treatment on admissions to chemical dependency treatment. Drug Alcohol Depend. 2010;110(1-2):126-36. 19. Rapp RC, Otto AL, Lane DT, Redko C, McGatha S, Carlson RG. Improving linkage with substance abuse treatment using brief case management and motivational interviewing. Drug Alcohol Depend. 2008;94(1-3):172-82. 20. Sorensen JL, Masson CL, Delucchi K, Sporer K, Barnett PG, Mitsuishi F, et al. Randomized trial of drug abuse treatment-linkage strategies. J Consult Clin Psychol. 2005;73(6):1026. 21. Strathdee SA, Ricketts EP, Huettner S, Cornelius L, Bishai D, Havens JR, et al. Facilitating entry into drug treatment among injection drug users referred from a needle exchange program: Results from a community-based behavioral intervention trial. Drug Alcohol Depend. 2006;83(3):225-32. 22. Metsch LR, Feaster DJ, Gooden L, Matheson T, Stitzer M, Das M, et al. Effect of patient navigation with or without financial incentives on viral suppression among hospitalized patients with HIV infection and substance use: a randomized clinical trial. JAMA. 2016;316(2):156-70. 23. Schwenker R, Dietrich CE, Hirpa S, Nothacker M, Smedslund G, Frese T, et al. Motivational interviewing for substance use reduction. Cochrane Database Syst Rev. 2023;12:CD008063. 24. Lozano BE, LaRowe SD, Smith JP, Tuerk P, Roitzsch J. Brief motivational feedback may enhance treatment entry in veterans with comorbid substance use and psychiatric disorders. Am J Addict. 2013;22(2):132-5. 25. McQueen J, Howe TE, Allan L, Mains D, Hardy V. Brief interventions for heavy alcohol users admitted to general hospital wards. Cochrane Database Syst Rev. 2011 Aug 10;2011(8):CD005191. 26. Wain RM, Wilbourne PL, Harris KW, Pierson H, Teleki J, Burling TA, et al. Motivational interview improves treatment entry in homeless veterans. Drug Alcohol Depend. 2011;115(1-2):113-9. 27. Ober AJ, Watkins KE, McCullough CM, Setodji CM, Osilla K, Hunter SB. Patient predictors of substance use disorder treatment initiation in primary care. J Subst Abuse Treat. 2018;90:64-72. 28. Polcin DL, Korcha R, Witbrodt J, Mericle AA, Mahoney E. Motivational Interviewing Case Management (MICM) for persons on probation or parole entering sober living houses. Crim Justice Behav. 2018;45(11):1634-59. 29. Gormley MA, Pericot-Valverde I, Diaz L, Coleman A, Lancaster J, Ortiz E, et al. Effectiveness of peer recovery support services on stages of the opioid use disorder treatment cascade: A systematic review. Drug Alcohol Depend. 2021;229:109123. 30. Magidson JF, Regan S, Powell E, Jack HE, Herman GE, Zaro C, et al. Peer recovery coaches in general medical settings: changes in utilization, treatment engagement, and opioid use. J Subst Abuse Treat. 2021;122:108248. 31. D’Onofrio G, O’Connor PG, Pantalon MV, Chawarski MC, Busch SH, Owens PH, et al. Emergency Department–Initiated Buprenorphine/Naloxone Treatment for Opioid Dependence: A Randomized Clinical Trial. JAMA. 2015 Apr 28;313(16):1636. 32. D’Onofrio G, Chawarski MC, O’Connor PG, Pantalon MV, Busch SH, Owens PH, et al. Emergency Department-Initiated Buprenorphine for Opioid Dependence with Continuation in Primary Care: Outcomes During and After Intervention. J Gen Intern Med. 2017 Jun 1;32(6):660-6. 33. Bogan C, Jennings L, Haynes L, Barth K, Moreland A, Oros M, et al. Implementation of emergency department–initiated buprenorphine for opioid use disorder in a rural southern state. J Subst Abuse Treat. 2020 Mar 1;112:73-8. 34. Liebschutz JM, Crooks D, Herman D, Anderson B, Tsui J, Meshesha LZ, et al. Buprenorphine Treatment for Hospitalized, Opioid-Dependent Patients: A Randomized Clinical Trial. JAMA Intern Med. 2014 Aug 1;174(8):1369-76. 35. Englander H, Dobbertin K, Lind BK, Nicolaidis C, Graven P, Dorfman C, et al. Inpatient Addiction Medicine Consultation and Post-Hospital Substance Use Disorder Treatment Engagement: a Propensity-Matched Analysis. J Gen Intern Med. 2019 Dec;34(12):2796-803. 36. Nordeck CD, Welsh C, Schwartz RP, Mitchell SG, Cohen A, O’Grady KE, et al. Rehospitalization and substance use disorder (SUD) treatment entry among patients seen by a hospital SUD consultation-liaison service. Drug Alcohol Depend. 2018 May;186:23-8. 37. Andrews G, Peters L. The psychometric properties of the Composite International Diagnostic Interview. Soc Psychiatry Psychiatr Epidemiol. 1998 Feb;33(2):80-8. 38. McNeely J, Wu LT, Subramaniam G, Sharma G, Cathers LA, Svikis D, et al. Performance of the Tobacco, Alcohol, Prescription Medication, and Other Substance Use (TAPS) Tool for Substance Use Screening in Primary Care Patients. Ann Intern Med. 2016;165(10):690-9. 39. Nordeck CD, Welsh C, Schwartz RP, Mitchell SG, O’Grady KE, Dunlap L, et al. Navigation Services to Avoid Rehospitalization among Medical/Surgical Patients with Comorbid Substance Use Disorder: Rationale and Design of a Randomized Controlled Trial. J Psychiatr Brain Sci. 2020;5(3):e200013. 40. McLellan AT, Cacciola JS, Zanis D. The addiction severity index-lite. Available from: https://adai.uw.edu/instruments/pdf/addiction_severity_index_lite_baseline_followup_5.pdf. Accessed 2023 Dec 21. 41. Skevington SM, Lotfy M, O’Connell KA. The World Health Organization’s WHOQOL-BREF quality of life assessment: Psychometric properties and results of the international field trial. A Report from the WHOQOL Group. Qual Life Res. 2004;13(2):299-310. 42. Kessler RC, Barker PR, Colpe LJ, Epstein JF, Gfroerer JC, Hiripi E, et al. Screening for Serious Mental Illness in the General Population. Arch Gen Psychiatry. 2003 Feb 1;60(2):184-9. 43. Schmotzer GL. Barriers and facilitators to participation of minorities in clinical trials. Ethn Dis. 2012 Spring;22(2):226-30. 44. Lloyd JJ, Ricketts EP, Strathdee SA, Cornelius LJ, Bishai D, Huettner S, et al. Social contextual factors associated with entry into opiate agonist treatment among injection drug users. Am J Drug Alcohol Abuse. 2005;31(4):555-70. 45. Lee CS, Liebschutz JM, Anderson BJ, Stein MD. Hospitalized opioid-dependent patients: Exploring predictors of buprenorphine treatment entry and retention after discharge. Am J Addict. 2017;26(7):667-72. 46. Akdağ EM, Kotan VO, Kose S, Tıkır B, Aydemir MÇ, Okay İT, et al. The relationship between internalized stigma and treatment motivation, perceived social support, depression and anxiety levels in opioid use disorder. Psychiatry Clin Psychopharmacol. 2018 Oct 2;28(4):394-401.

引用本文

Courtney D. Nordeck*,Anjalee Sharma,Mishka Terplan,Kristi Dusek,Elizabeth Gilliams,Jan Gryczynski. Opioid Use Disorder Treatment Linkage at Strategic Touchpoints Using Buprenorphine (OUTLAST-B): Rationale, Design, and Evolution of a Randomized Controlled Trial, Journal of Psychiatry and Brain Science. 2023; 8; (6). https://doi.org/10.20900/jpbs.20230010.

文献评论

相关学者

相关机构